Samsung Biologics Completes Third-Party Verification of Product Carbon Footprint System

Objectivity and Reliability of PCF System Verified
John Rim: "Strengthening Trust with Customers"

Samsung Biologics has completed third-party verification of its Product Carbon Footprint (PCF) system and has moved to strengthen its ESG (Environmental, Social and Governance) management.

Samsung Biologics announced on the 8th that it held a presentation ceremony for the PCF system third-party verification certificate at its headquarters in Songdo, Incheon, on the 6th. The verification was conducted by DNV, a global certification body based in Norway. DNV provides verification and certification services related to quality, environment, and safety based on international standards across various industries, including energy, manufacturing, and biopharmaceuticals.

Lee Jangseop, CEO of DNV Korea (left), and Yoo Seungho, Head of the Management Support Center and Vice President at Samsung Biologics, are posing for a commemorative photo at the award ceremony held on the 6th at the company headquarters in Songdo, Incheon. Samsung Biologics

PCF refers to the amount of greenhouse gas emissions generated throughout the entire lifecycle of a product, from production to disposal. This verification covered the biopharmaceutical manufacturing processes at the company’s First Bio Campus. Samsung Biologics stated, “We have been officially recognized not only for the objectivity and reliability of our internally built PCF system, but also for carrying out activities that align with the ESG environmental strategies required by our global customers.”

Through this verification, it was demonstrated that Samsung Biologics’ PCF system accurately calculates greenhouse gas emissions generated during energy and raw and subsidiary material use, as well as waste and wastewater discharge, across the entire pharmaceutical production process. The company’s PCF system met all the requirements of the international standard ISO 14067, which defines the principles for quantifying and reporting product carbon footprints, and PAS 2050, the product life cycle carbon footprint assessment framework of the British Standards Institution (BSI).

Recently, major global customers have been emphasizing efforts to reduce greenhouse gas emissions in the manufacturing process by treating PCF systems as a key criterion for implementing carbon neutrality and explicitly including them in contracts. Building on the acquisition of this PCF verification, Samsung Biologics plans to continue its efforts to achieve carbon neutrality targets to strengthen trust with customers, including by gradually expanding the number of verified sites.

John Rim, CEO of Samsung Biologics, said, “This verification has created an opportunity for us to meet the requirements of our global customers and further strengthen our relationships of trust,” adding, “As a leading ESG company in the pharmaceutical and biopharmaceutical industry, Samsung Biologics will continue to work toward achieving its carbon neutrality goals.”